RT Journal Article
SR Electronic
T1 Antimicrobial susceptibility patterns of respiratory Gram-negative bacterial isolates from COVID-19 patients in Switzerland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.10.21253079
DO 10.1101/2021.03.10.21253079
A1 Gysin, Marina
A1 Acevedo, Claudio Tirso
A1 Haldimann, Klara
A1 Bodendoerfer, Elias
A1 Imkamp, Frank
A1 Bulut, Karl
A1 Buehler, Philipp Karl
A1 Brugger, Silvio Daniel
A1 Becker, Katja
A1 Hobbie, Sven N.
YR 2021
UL http://medrxiv.org/content/early/2021/07/17/2021.03.10.21253079.abstract
AB Background Bacterial superinfections associated with COVID-19 are common in ventilated ICU patients and impact morbidity and lethality. However, the contribution of antimicrobial resistance to the manifestation of bacterial infections in these patients has yet to be elucidated.Methods We collected 70 Gram-negative bacterial strains, isolated from the lower respiratory tract of ventilated COVID-19 patients in Zurich, Switzerland between March and May 2020. Species identification was performed using MALDI-TOF; antibiotic susceptibility profiles were determined by EUCAST disk diffusion and CLSI broth microdilution assays. Selected Pseudomonas aeruginosa isolates were analyzed by whole-genome sequencing.Results P. aeruginosa (46%) and Enterobacterales (36%) comprised the two largest etiologic groups. Drug resistance in P. aeruginosa isolates was high for piperacillin/tazobactam (65.6%), cefepime (56.3%), ceftazidime (46.9%) and meropenem (50.0%). Enterobacterales isolates showed slightly lower levels of resistance to piperacillin/tazobactam (32%), ceftriaxone (32%), and ceftazidime (36%). All P. aeruginosa isolates and 92% of Enterobacterales isolates were susceptible to aminoglycosides, with apramycin found to provide best-in-class coverage. Genotypic analysis of consecutive P. aeruginosa isolates in one patient revealed a frameshift mutation in the transcriptional regulator nalC that coincided with a phenotypic shift in susceptibility to β-lactams and quinolones.Conclusions Considerable levels of antimicrobial resistance may have contributed to the manifestation of bacterial superinfections in ventilated COVID-19 patients, and may in some cases mandate consecutive adaptation of antibiotic therapy. High susceptibility to amikacin and apramycin suggests that aminoglycosides may remain an effective second-line treatment of ventilator-associated bacterial pneumonia, provided efficacious drug exposure in lungs can be achieved.Competing Interest StatementSNH is a co-founder of Juvabis AG, a startup biotech company with an interest in aminoglycoside therapeutics. All other authors declare no competing interests.Funding StatementThis work was supported by an Innosuisse grant (project no. 45893.1 INNO-LS) and by the University of Zurich, Institute of Medical Microbiology. This work was also supported by the Clinical Research Priority Program of the University of Zurich for the CRPP Precision medicine for bacterial infections. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. SDB is supported by a Fellowship from the Promedica Foundation (1449/M).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Local Ethics Committee of the Canton of Zurich, Switzerland (Kantonale Ethikkommission Zurich BASEC ID 2020 - 00646)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data has been made available in the manuscript and/or its supplementary information.AMIAmikacinAMCAmoxicillin/clavulanateAPRApramycinASTAntimicrobial Susceptibility TestingCIPCiprofloxacinCLSIClinical and Laboratory Standards InstituteCROCeftriaxoneCSTColistinCAZCeftazidimeCZACeftazidime/avibactamECOFFEpidemiological CutoffEUCASTEuropean Committee on Antimicrobial Susceptibility TestingFEPCefepimeGENGentamicinGNBGram-negative bacilliMEMMeropenemMICMinimal Inhibitory ConcentrationPLZPlazomicinSXTTrimethoprim/sulfamethoxazoleTOBTobramycinTZPPiperacillin/tazobactam